13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BO29554 B.FAST

    Acronym: 

    BO29554 B.FAST

    ACTRN/NCT /ethics: 

    NCT03178552

    Scientific title: 

    A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III Tumour Stream Non-small lung cancer
    Age Range 18 years and older Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2017-09-22
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small lung cancer
    Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Anticipated Start Date 2017-09-22
    Anticipated End Date

    Trial Summary

    This is a phase II/III, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

    Lay Summary

    A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

    Sponsor / Cooperative group

    Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting